B of A Securities Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $30
B of A Securities analyst Tazeen Ahmad maintains ACADIA Pharmaceuticals (NASDAQ: ACAD ) with a Buy and raises the price target from $29 to $30.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.